The estimated Net Worth of Rachel Humphrey is at least $513 Tausend dollars as of 2 March 2018. Dr Humphrey owns over 16,160 units of Black Diamond Therapeutics Inc stock worth over $284,395 and over the last 9 years he sold BDTX stock worth over $0. In addition, he makes $228,888 as Advisor at Black Diamond Therapeutics Inc.
Sign up
Dr D BDTX stock SEC Form 4 insiders trading
Dr has made over 5 trades of the Black Diamond Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 16,160 units of BDTX stock worth $106,818 on 2 March 2018.
The largest trade he's ever made was exercising 23,840 units of Black Diamond Therapeutics Inc stock on 28 February 2018 worth over $157,582. On average, Dr trades about 7,759 units every 39 days since 2016. As of 2 March 2018 he still owns at least 46,394 units of Black Diamond Therapeutics Inc stock.
You can see the complete history of Dr Humphrey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Rachel Wallach Humphrey M.D., Ph.D. biography
Dr. Rachel Wallach Humphrey M.D., Ph.D. is the Advisor at Black Diamond Therapeutics Inc.
What is the salary of Dr D?
As the Advisor of Black Diamond Therapeutics Inc, the total compensation of Dr D at Black Diamond Therapeutics Inc is $228,888. There are 6 executives at Black Diamond Therapeutics Inc getting paid more, with David Epstein having the highest compensation of $3,346,080.
How old is Dr D?
Dr D is 60, he's been the Advisor of Black Diamond Therapeutics Inc since . There are 5 older and 13 younger executives at Black Diamond Therapeutics Inc. The oldest executive at Black Diamond Therapeutics Inc is Robert Ingram, 77, who is the Independent Chairman of the Board.
What's Dr D's mailing address?
Rachel's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE, MA, 02142.
Insiders trading at Black Diamond Therapeutics Inc
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah und Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.
What does Black Diamond Therapeutics Inc do?
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
What does Black Diamond Therapeutics Inc's logo look like?
Complete history of Dr Humphrey stock trades at CytomX Therapeutics Inc und Black Diamond Therapeutics Inc
Black Diamond Therapeutics Inc executives and stock owners
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Epstein,
President, Chief Executive Officer, Director -
Thomas Leggett,
Chief Financial Officer -
Christopher Roberts,
Chief Scientific Officer -
Dr. David M. Epstein Ph.D.,
Co-Founder, Pres, CEO & Director -
Brent Hatzis-Schoch Esq., J.D.,
COO & Gen. Counsel -
Samarth Kulkarni,
Independent Director -
Dr. Rachel Wallach Humphrey M.D., Ph.D.,
Advisor -
Garry Menzel,
Independent Director -
Rajeev Shah,
Independent Director -
Ali Behbahani,
Independent Director -
Alexander Mayweg,
Director -
Bradley Bolzon,
Director -
Fang Ni,
Chief Business Officer -
Rachel Humphrey,
Chief Medical Officer -
Karsten Witt,
Senior Vice President - Non-Clinical Development -
Elizabeth Buck,
Executive Vice President - Discovery and Translational Services -
Brent Hatzis-Schoch,
Chief Operating Officer, General Counsel -
Robert Ingram,
Independent Chairman of the Board -
Tai-An Lin Ph.D.,
VP & Head of Biology -
Dr. Karsten Witt M.D.,
Sr. VP of Clinical Devel. & Interim Chief Medical Officer -
Dr. Christopher D. Roberts Ph.D.,
Advisor -
Erika Jones,
VP of Fin., Corp. Controller & Principal Accounting Officer -
Dr. Fang Ni Pharm.D.,
CFO, Principal Financial Officer and Chief Bus. Officer -
Dr. Elizabeth Buck Ph.D.,
Co-Founder & Chief Scientific Officer -
James E Deerfield Mgmt L.P....,
-
Sergey Yurasov,
CHIEF MEDICAL OFFICER -
Shannon Campbell,
-
Prakash Raman,
-
Venture Capital Vi, L.P.Ver...,
-
Biomedical Innovation Maste...,
10% owner -
Venture Capital Vi, L.P.Ver...,
-
Erika Jones,
SEE REMARKS -
Wendy L Dixon,
-
Growth N Vbb Biotech Ag Bio...,
-
Kapil Dhingra,
-
Capital Management, L.P.Ra ...,
-
Mark A. Velleca,
PRESIDENT & CEO